ClinicalTrialsFinder
CompletedPhase 3ACTRN12607000152426

Randomised trial of dopamine vs dobutamine for treatment of low systemic blood flow in very preterm infants

Sponsor

A/Prof Nick Evans

Enrollment

45 participants

Start Date

Oct 1, 1998

Study Type

Interventional

Conditions

Low systemic blood flow in preterm infants

Summary

Low systemic blood flow in the early hours after birth is a common problem in very preterm babies. It is associated with a range of adverse outcomes. This trial aims to test the efficacy of the two commonly used inotropes in preterm babies. Inotropes are drugs that improve the pumping performance of the heart.

Eligibility

Sex: Both males and femalesMax Age: 30 Weekss

Plain Language Summary

Simplified for easier understanding

This trial compares two medications — dopamine and dobutamine — for treating low blood flow in very premature babies born before 30 weeks of pregnancy. The study aims to determine which drug better improves blood circulation in these vulnerable newborns. Babies with major brain bleeding before treatment starts are not eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Dopamine vs dobutamine by continuous intravenous infusion. Two dosage steps for each drug. 10 and 20 micrograms/kg/min. If Doppler ultrasound measures of systemic blood flow increased on 10 microgram/

Dopamine vs dobutamine by continuous intravenous infusion. Two dosage steps for each drug. 10 and 20 micrograms/kg/min. If Doppler ultrasound measures of systemic blood flow increased on 10 microgram/kg/min then they remain on that dose. If no increase in systemic blood flow at 10 micrograms/kg/min then they increased to 20 micrograms/kg/min. If they increased systemic blood flow on 20 micrograms/kg/min then they remain on that dose. If no increase in systemic blood flow at 20 micrograms/kg/min then crossover immediately to the other drug with no washout period and the dose escalation process repeated with the other syringe (drug). The infusion was maintained until 24 hours of age then weaned at the discretion of the treating medical staff.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000152426